A Phase 1 interventional study of ACT-777991 (SAD) and ACT-777991 (MAD) in Healthy, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-21.
Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A study to examine the safety, tolerability, and pharmacokinetics of single- and multiple-ascending doses of ACT-777991 in healthy subjects.
Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.
Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
General Inclusion Criteria:
Inclusion Criteria for Part B:
General Exclusion Criteria:
Exclusion Criteria for the absorption,distribution, metabolism and excretion (ADME) evaluation:
Exclusion Criteria for Part B:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose A1 of ACT-777991.
Drug: ACT-777991 (SAD) · Drug: Placebo (SAD)
Single dose A2 of ACT-777991.
Drug: ACT-777991 (SAD) · Drug: Placebo (SAD)
Single dose A3 of ACT-777991.
Drug: ACT-777991 (SAD) · Drug: Placebo (SAD)
Single dose A4 of ACT-777991 under fasted and fed conditions, separated by at least 14 days.
Drug: ACT-777991 (SAD) · Drug: Placebo (SAD)
Single dose A5 of ACT-777991.
Drug: ACT-777991 (SAD) · Drug: Placebo (SAD)
Single dose A6 of ACT-777991.
Drug: ACT-777991 (SAD) · Drug: Placebo (SAD)
Single dose A7 of ACT-777991.
Drug: ACT-777991 (SAD) · Drug: Placebo (SAD)
Single dose A8 of ACT-777991.
Drug: ACT-777991 (SAD) · Drug: Placebo (SAD)
Multiple doses B1 of ACT-777991.
Drug: ACT-777991 (MAD) · Drug: Placebo (MAD)
Multiple doses B2 of ACT-777991.
Drug: ACT-777991 (MAD) · Drug: Placebo (MAD)
Multiple doses B3 of ACT-777991.
Drug: ACT-777991 (MAD) · Drug: Placebo (MAD)
Multiple doses B4 of ACT-777991.
Drug: ACT-777991 (MAD) · Drug: Placebo (MAD)
Multiple doses B5 of ACT-777991.
Drug: ACT-777991 (MAD) · Drug: Placebo (MAD)
Single dose of ACT-777991 plus a single dose of 14C-ACT-777991. At one of the dose levels from A4 to A8.
Drug: 14C-ACT-777991 microtracer (SAD - Absolute Bioavailability) · Drug: Microtracer matching placebo (SAD - Absolute Bioavailability)
Multiple doses of ACT-777991 plus a single dose of 14C-ACT-777991. At one of the dose levels from B1 to B5.
Drug: 14C-ACT-777991 microtracer (MAD - ADME) · Drug: Microtracer matching placebo (MAD - ADME)
ACT-777991 administered as hard capsules for oral use.
ACT-777991 administered as hard capsules for oral use, once daily.
ACT-777991 matching placebo administered as hard capsules for oral use.
Matching placebo administered as hard capsules for oral use, once daily.
Single dose of 14C-ACT-777991 microtracer, administered intravenously.
Single dose of 14C-ACT-777991 microtracer matching placebo, administered intravenously.
Single dose of 14C-ACT-777991 microtracer, oral solution..
Single dose of 14C-ACT-777991 microtracer matching placebo, oral solution.
Incidence of treatment-emergent adverse events.
Time frame: From first dose on Day 1 to Day 4 after the last dose was administered
All cohorts: Area under the plasma concentration-time curve (AUC) from zero to time t of the last measured concentration above the limit of quantification (AUC0-t) of ACT-777991
Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered
All cohorts: Area under the plasma concentration-time curve (AUC) from zero to infinity (AUC0-inf) of ACT-777991
Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered
All cohorts: Maximum plasma concentration (Cmax) of ACT-777991
Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered
All cohorts: Time to reach Cmax (tmax) of ACT-777991
Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered
All cohorts: Terminal half-life (t1/2) of ACT-777991
Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered
Part A (SAD): Absolute bioavailability of ACT-777991
Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered
Part B (MAD): Excretion of radioactivity in urine and feces
Time frame: Samples will be collected at predefined time points from Day 1 to Day X+3 (where Day X = day of last study treatment administration)
Part B (MAD): AUC during a dosing interval (AUCτ) following the first and the last dose of ACT-777991.
Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered
Part A (SAD): Food effect evaluation only: AUC0-inf of ACT-777991 under fed conditions
Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4.
Part A (SAD): Food effect evaluation only: Cmax of ACT-777991 under fed conditions
Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4.
Part A (SAD): Food effect evaluation only: tmax of ACT-777991 under fed conditions
Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4.
Part A (SAD): Food effect evaluation only: t1/2 of ACT 777991 under fed conditions
Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4.
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2021 to primary completion in Jan 2022, 11 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Idorsia Pharmaceuticals Ltd. →